# Study Testing the Biologic Activity and Safety of an Immunotherapeutic in Patients With Newly Diagnosed Stage IV Kidney Cancer

> **NCT00272649** · PHASE1,PHASE2 · COMPLETED · sponsor: **Argos Therapeutics** · enrollment: 22 (actual)

## Conditions studied

- Renal Cell Carcinoma

## Interventions

- **BIOLOGICAL:** AGS-003

## Key facts

- **NCT ID:** NCT00272649
- **Lead sponsor:** Argos Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-01
- **Primary completion:** 2012-02
- **Final completion:** 2012-02
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2013-03-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00272649

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00272649, "Study Testing the Biologic Activity and Safety of an Immunotherapeutic in Patients With Newly Diagnosed Stage IV Kidney Cancer". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT00272649. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*